Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 21 November 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Methotrexate induces remission in refractory Crohn's disease

Research reported in this month's Cochrane Database of Systematic Reviews recommends the use of methotrexate 25 mg intramuscularly weekly for induction of remission and complete withdrawal from steroids in patients with refractory Crohn's.

News image

fiogf49gjkf04

Although corticosteroids are effective for induction of remission of Crohn's disease, approximately 20% of patients who respond relapse when steroids are withdrawn and become steroid dependent.

Furthermore, corticosteroids exhibit significant adverse effects.

The success of methotrexate as a treatment for rheumatoid arthritis led to its evaluation in patients with refractory Crohn's disease.

Methotrexate has been studied for induction of remission of refractory Crohn's disease and has become the principal alternative to azathioprine/6MP therapy.

The evidence for its effectiveness has not been subjected to a systematic review.

Dr Alfadhli and colleagues conducted a systematic review of the evidence for effectiveness of methotrexate for induction of remission with active Crohn's disease.

The researchers looked at active Crohn’s disease in the presence and absence of concomitant steroid therapy.

3 small studies were identified that used low doses of methotrexate orally
The Cochrane Database of Systematic Reviews

The research team conducted a computer-assisted search of MEDLINE and EMBASE for randomized controlled trials involving patients of age more than 17 years.

The team searched for relevant studies published in English, French, Spanish, Italian and German between 1966 and 2004.

Manual searches of reference lists from potentially relevant papers were performed to identify additional studies.

In addition, the researchers searched the Cochrane Controlled Trials Register as well as the Inflammatory Bowel Disease Review Group Specialized Trials Register.

The team defined refractory Crohn's disease by conventional clinical, radiological and endoscopic criteria, categorized as being active with a disease activity index more than 150.

The outcome measure was the rate of induction of remission and complete withdrawal from steroids in treatment and control groups after more than 16 weeks.

The investigators included a secondary outcome of induction of remission and reduction in steroid dose of at least 50%.

The results of the searches above were reviewed independently by two observers and relevant studies were selected according to the predefined selection criteria.

The team resolved any disagreement by consensus and used a standard data extraction form.

The same two researchers assessed the methodological quality of each trial by considering details of randomization method and whether intention-to-treat analysis was possible from the published data.

The quality of each trial was also assessed by the number of patients lost to follow-up, and whether a blinded outcome assessment was used.

In considering the appropriateness of combining results, the researchers first assessed trials according to the clinical comparability of trial protocols and study populations.

The investigators identified 5 randomized trials and these were considered inappropriate to combine because they differed with respect to participants, intervention, and outcomes.

The team found 3 small studies which employed low doses of methotrexate orally.

The pooled results of these 3 studies showed no statistically significant difference between methotrexate and placebo/control medication treated patients.

The investigators identified 1 small study which used a higher dose of intravenous/oral methotrexate that showed no statistically significant difference.

A larger study which employed a higher dose of methotrexate intramuscularly showed substantial benefit.

The researchers found adverse effects were more common with high dose intramuscular methotrexate therapy than with placebo.

Dr Alfadhli concludes, “There is evidence from a single large randomized trial on which to recommend the use of methotrexate 25 mg intramuscularly weekly for induction of remission and complete withdrawal from steroids in patients with refractory Crohn's disease.”

“Although adverse effects were more common than with placebo, they were not severe.”

“There is no evidence on which to base a recommendation for use of lower dose oral methotrexate.”

The Cochrane Database Syst Rev 2005: 2. Art. No.: CD003459.pub2. DOI: 10.1002/14651858.CD003459.pub2.
11 May 2005

Go to top of page Email this page Email this page to a colleague

 21 November 2017 
Prepregnancy obesity and maternal mortality
 21 November 2017 
Preoperative optimization in IBD patients
 21 November 2017 
Cholangiopathy in critically ill patients
 20 November 2017 
Barriers to hepatitis C treatment
 20 November 2017 
Socioeconomic characteristics in diverticular disease
 20 November 2017 
Endoscopic indices of disease activity for Crohn’s
 17 November 2017 
Food elimination diets for treatment of adults with eosinophilic esophagitis
 17 November 2017 
PPI use and cognitive function in women
 17 November 2017 
Predicting microscopic colitis
 16 November 2017 
NAFLD-hepatocellular carcinoma and survival after orthotopic liver transplant
 16 November 2017 
Prepregnancy obesity and severe maternal morbidity
 16 November 2017 
Celiac disease screening in adult first-degree relatives
 15 November 2017 
Breastfeeding and the risk of IBD
 15 November 2017 
Medication nonadherence and health care costs
 15 November 2017 
Predicting recurrence after curative rectal cancer surgery
 14 November 2017 
HBV/HCV coinfection and cirrhosis
 14 November 2017 
Sexual dysfunction after rectal cancer surgery
 14 November 2017 
Eosinophilic gastroenteritis and colitis
 13 November 2017 
GI bleeding in patients taking non–vitamin K antagonist oral anticoagulants
 13 November 2017 
Genetic polymorphisms, fatty acids and ulcerative colitis
 13 November 2017 
Flares after immunomodulator withdrawal in Crohn's
 10 November 2017 
Thiopurines vs TNF and lymphoma risk in IBD
 10 November 2017 
Drug monitoring of anti-tumour necrosis factor therapy in IBD
 10 November 2017 
Treatment decisions for older patients with colorectal cancer
 09 November 2017 
Quality standards in upper gastrointestinal endoscopy
 09 November 2017 
Irradiated rectal cancer and chemoradiotherapy
 09 November 2017 
Environmental factors and IBD
 08 November 2017 
Prophylaxis of spontaneous bacterial peritonitis
 08 November 2017 
Optimal management of postoperative Crohn's disease
 07 November 2017 
Community Screening for Helicobacter pylori
 07 November 2017 
Early readmission in IBD patients
 07 November 2017 
Mesocolic excision for colon cancer
 06 November 2017 
Food elimination diet for children with eosinophilic esophagitis
 06 November 2017 
Biologic agents and obesity in children with IBD
 06 November 2017 
Liver cancer burden despite extensive use of antiviral agents
 03 November 2017 
Statins and mortality in chronic viral hepatitis
 03 November 2017 
Propofol for outpatient colonoscopy
 03 November 2017 
Asthma and IBD development
 02 November 2017 
Diverticulitis and emergency department burden
 02 November 2017 
Sexual functioning in Hep C
 02 November 2017 
Rural residence and risk of IBD
 01 November 2017 
Heartburn relief in adolescents with GERD
 01 November 2017 
Autoimmune pancreatitis in children
 31 October 2017 
Follow-up of positive results on fecal blood tests
 31 October 2017 
Surveillance in ulcerative colitis and Crohn’s disease
 30 October 2017 
Local recurrence after curative rectal cancer surgery
 30 October 2017 
Low-flow ascites pump in refractory cirrhosis
 30 October 2017 
Medical therapy of patients with pediatric-onset IBD
 27 October 2017 
NAFLD in advanced fibrosis in the USA
 27 October 2017 
Early readmission in cirrhosis after bacterial infections
 26 October 2017 
Predicting response to anti-TNF therapy in Crohn's
 26 October 2017 
Conversion to open laparotomy in rectal cancer
 25 October 2017 
Conversion of colonoscopy to sigmoidoscopy
 25 October 2017 
Fecal microbiota transplantation
 25 October 2017 
Rifaximin and survival in hepatic encephalopathy
 24 October 2017 
Eosinophilic esophagitis with swallowed topical corticosteroids
 24 October 2017 
Meta-analysis in nutritiona research
 23 October 2017 
NAFLD-related hepatocellular carcinoma in liver resection
 23 October 2017 
Outcome of hepatic sarcoidosis
 20 October 2017 
Conversion of planned colonoscopy to sigmoidoscopy

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us